CN114504110A - Composition for regulating and improving intestinal dysbacteriosis and preparation method thereof - Google Patents
Composition for regulating and improving intestinal dysbacteriosis and preparation method thereof Download PDFInfo
- Publication number
- CN114504110A CN114504110A CN202210140923.1A CN202210140923A CN114504110A CN 114504110 A CN114504110 A CN 114504110A CN 202210140923 A CN202210140923 A CN 202210140923A CN 114504110 A CN114504110 A CN 114504110A
- Authority
- CN
- China
- Prior art keywords
- parts
- lactobacillus
- freeze
- bifidobacterium
- intestinal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000000968 intestinal effect Effects 0.000 title claims abstract description 77
- 239000000203 mixture Substances 0.000 title claims abstract description 65
- 230000001105 regulatory effect Effects 0.000 title claims abstract description 49
- 208000036649 Dysbacteriosis Diseases 0.000 title claims abstract description 41
- 208000027244 Dysbiosis Diseases 0.000 title claims abstract description 41
- 230000007140 dysbiosis Effects 0.000 title claims abstract description 41
- 238000002360 preparation method Methods 0.000 title claims description 16
- 240000006024 Lactobacillus plantarum Species 0.000 claims abstract description 50
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims abstract description 50
- 229940072205 lactobacillus plantarum Drugs 0.000 claims abstract description 50
- 240000001046 Lactobacillus acidophilus Species 0.000 claims abstract description 47
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims abstract description 47
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims abstract description 47
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims abstract description 46
- 241000186016 Bifidobacterium bifidum Species 0.000 claims abstract description 33
- 229940002008 bifidobacterium bifidum Drugs 0.000 claims abstract description 29
- 241001608472 Bifidobacterium longum Species 0.000 claims abstract description 25
- 229940009291 bifidobacterium longum Drugs 0.000 claims abstract description 25
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 claims abstract description 24
- 229920001202 Inulin Polymers 0.000 claims abstract description 24
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 claims abstract description 24
- 229940009289 bifidobacterium lactis Drugs 0.000 claims abstract description 24
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims abstract description 24
- 229940107187 fructooligosaccharide Drugs 0.000 claims abstract description 24
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims abstract description 24
- 229940029339 inulin Drugs 0.000 claims abstract description 24
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 claims abstract description 24
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 claims abstract description 23
- 241000186012 Bifidobacterium breve Species 0.000 claims abstract description 22
- 229920001353 Dextrin Polymers 0.000 claims abstract description 21
- 239000004375 Dextrin Substances 0.000 claims abstract description 21
- 235000019425 dextrin Nutrition 0.000 claims abstract description 21
- 239000000832 lactitol Substances 0.000 claims abstract description 21
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 claims abstract description 21
- 229960003451 lactitol Drugs 0.000 claims abstract description 21
- 235000010448 lactitol Nutrition 0.000 claims abstract description 21
- 239000000463 material Substances 0.000 claims abstract description 20
- 238000002156 mixing Methods 0.000 claims abstract description 16
- 239000007788 liquid Substances 0.000 claims description 61
- 238000000855 fermentation Methods 0.000 claims description 39
- 230000004151 fermentation Effects 0.000 claims description 39
- 239000000843 powder Substances 0.000 claims description 36
- 239000001963 growth medium Substances 0.000 claims description 35
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 30
- 238000012258 culturing Methods 0.000 claims description 24
- 239000002994 raw material Substances 0.000 claims description 18
- 238000003756 stirring Methods 0.000 claims description 18
- 238000005119 centrifugation Methods 0.000 claims description 15
- 238000004945 emulsification Methods 0.000 claims description 15
- 238000004108 freeze drying Methods 0.000 claims description 15
- 238000005469 granulation Methods 0.000 claims description 15
- 230000003179 granulation Effects 0.000 claims description 15
- 229910052757 nitrogen Inorganic materials 0.000 claims description 15
- 238000001816 cooling Methods 0.000 claims description 14
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 235000020183 skimmed milk Nutrition 0.000 claims description 12
- 238000009928 pasteurization Methods 0.000 claims description 9
- 238000005086 pumping Methods 0.000 claims description 9
- 230000001954 sterilising effect Effects 0.000 claims description 9
- 238000004806 packaging method and process Methods 0.000 claims description 6
- 238000011218 seed culture Methods 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- AYRXSINWFIIFAE-SCLMCMATSA-N Isomaltose Natural products OC[C@H]1O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@@H](O)[C@@H](O)[C@@H]1O AYRXSINWFIIFAE-SCLMCMATSA-N 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 238000004090 dissolution Methods 0.000 claims description 3
- 230000003716 rejuvenation Effects 0.000 claims description 2
- 239000008176 lyophilized powder Substances 0.000 claims 3
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 30
- 210000004347 intestinal mucosa Anatomy 0.000 abstract description 18
- 230000004888 barrier function Effects 0.000 abstract description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 16
- 201000010099 disease Diseases 0.000 abstract description 10
- 230000009286 beneficial effect Effects 0.000 abstract description 7
- 230000006378 damage Effects 0.000 abstract description 6
- 239000006041 probiotic Substances 0.000 abstract description 6
- 235000018291 probiotics Nutrition 0.000 abstract description 6
- 230000002195 synergetic effect Effects 0.000 abstract description 5
- 235000013305 food Nutrition 0.000 abstract description 4
- 230000008439 repair process Effects 0.000 abstract description 4
- 235000013325 dietary fiber Nutrition 0.000 abstract description 3
- 235000013406 prebiotics Nutrition 0.000 abstract description 3
- 229920002774 Maltodextrin Polymers 0.000 abstract description 2
- 239000005913 Maltodextrin Substances 0.000 abstract description 2
- 229930006000 Sucrose Natural products 0.000 abstract description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 abstract description 2
- 239000000686 essence Substances 0.000 abstract description 2
- 235000013376 functional food Nutrition 0.000 abstract description 2
- 230000007774 longterm Effects 0.000 abstract description 2
- 229940035034 maltodextrin Drugs 0.000 abstract description 2
- 239000000049 pigment Substances 0.000 abstract description 2
- 229960004793 sucrose Drugs 0.000 abstract description 2
- 241000894006 Bacteria Species 0.000 description 23
- 230000000694 effects Effects 0.000 description 17
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 14
- 206010010774 Constipation Diseases 0.000 description 10
- 206010012735 Diarrhoea Diseases 0.000 description 10
- 230000002829 reductive effect Effects 0.000 description 9
- 208000004998 Abdominal Pain Diseases 0.000 description 8
- 244000052616 bacterial pathogen Species 0.000 description 8
- 206010000060 Abdominal distension Diseases 0.000 description 7
- 241000186000 Bifidobacterium Species 0.000 description 7
- 206010006326 Breath odour Diseases 0.000 description 7
- 208000032139 Halitosis Diseases 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 235000012000 cholesterol Nutrition 0.000 description 7
- 230000013872 defecation Effects 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 230000035755 proliferation Effects 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 206010020751 Hypersensitivity Diseases 0.000 description 6
- 231100000460 acute oral toxicity Toxicity 0.000 description 6
- 208000026935 allergic disease Diseases 0.000 description 6
- 230000007815 allergy Effects 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 241000186660 Lactobacillus Species 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 208000008589 Obesity Diseases 0.000 description 4
- 206010067171 Regurgitation Diseases 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 229940039696 lactobacillus Drugs 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 239000002207 metabolite Substances 0.000 description 4
- 235000020824 obesity Nutrition 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 150000004666 short chain fatty acids Chemical class 0.000 description 4
- 230000036578 sleeping time Effects 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 3
- 108010062877 Bacteriocins Proteins 0.000 description 3
- 241000606125 Bacteroides Species 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000006838 adverse reaction Effects 0.000 description 3
- 239000003833 bile salt Substances 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 238000003359 percent control normalization Methods 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 108010000231 Choloylglycine hydrolase Proteins 0.000 description 2
- 241000193403 Clostridium Species 0.000 description 2
- 101710146739 Enterotoxin Proteins 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 108010065805 Interleukin-12 Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000306 component Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000000147 enterotoxin Substances 0.000 description 2
- 231100000655 enterotoxin Toxicity 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000005027 intestinal barrier Anatomy 0.000 description 2
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 2
- 230000004673 intestinal mucosal barrier function Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000004792 oxidative damage Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000000529 probiotic effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- -1 superoxide anions Chemical class 0.000 description 2
- 230000001839 systemic circulation Effects 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 1
- WFJIVOKAWHGMBH-UHFFFAOYSA-N 4-hexylbenzene-1,3-diol Chemical compound CCCCCCC1=CC=C(O)C=C1O WFJIVOKAWHGMBH-UHFFFAOYSA-N 0.000 description 1
- 206010054196 Affect lability Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000034309 Bacterial disease carrier Diseases 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- 241000588914 Enterobacter Species 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 241001591005 Siga Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 102000000591 Tight Junction Proteins Human genes 0.000 description 1
- 108010002321 Tight Junction Proteins Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000003181 biological factor Substances 0.000 description 1
- 230000007177 brain activity Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000021045 dietary change Nutrition 0.000 description 1
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005428 food component Substances 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 210000004837 gut-associated lymphoid tissue Anatomy 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002366 mineral element Substances 0.000 description 1
- 239000006872 mrs medium Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 235000021391 short chain fatty acids Nutrition 0.000 description 1
- 230000003860 sleep quality Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001578 tight junction Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/718—Starch or degraded starch, e.g. amylose, amylopectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/733—Fructosans, e.g. inulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/113—Acidophilus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/175—Rhamnosus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/517—Bifidum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/519—Breve
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/531—Lactis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/533—Longum
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
The invention relates to the technical field of food, and discloses a composition for regulating and improving intestinal dysbacteriosis, which is prepared by mixing isomaltooligosaccharide, inulin, lactitol, fructo-oligosaccharide, lactobacillus plantarum, stachyose, resistant dextrin, bifidobacterium lactis, bifidobacterium bifidum, lactobacillus acidophilus, bifidobacterium longum, bifidobacterium breve and lactobacillus rhamnosus. Compared with the prior art, the invention has the following beneficial effects: the composition provided by the invention starts from the reasons of the constant value of probiotics in the intestinal tract, the repair of intestinal mucosa barrier damage and the like, and achieves the purpose of effectively regulating and improving the diseases related to the imbalance of the intestinal flora through the mutual matching and synergistic action of the components; the invention does not add auxiliary materials such as cane sugar, maltodextrin, pigment, essence and the like, and simultaneously adds prebiotics and dietary fibers, promotes the colonization of probiotics in intestinal tracts, is safe and reliable, and can be used as a functional food for improving the intestinal flora imbalance diseases after long-term consumption.
Description
Technical Field
The invention belongs to the technical field of food, and particularly relates to a composition for regulating and improving intestinal dysbacteriosis and a preparation method thereof.
Background
Food is broken down through the stomach and small intestine, digested and enters the large intestine. The intestinal flora utilizes food components, partial metabolites, intestinal mucus and the like which are not completely digested by a human body to carry out metabolic activity and maintain the number balance of the intestinal flora, and influences the health of a host in multiple aspects through various physiological activities of the intestinal flora. A large number of microorganisms exist in the intestinal tract of a human body, about 1000-1150 bacteria, more than 100 trillion bacteria, which are 10 times of the number of cells of the human body. The intestinal flora of the human body is associated with the human body from the birth of the infant, forms an indispensable microecosystem with strong functions for the human body, plays a great role in various aspects of human nutrition, metabolism, diseases and the like, and influences the development and health of the human body. The normal flora of the gastrointestinal tract hardly changes in a human life. The normal adult gastrointestinal flora pattern is quite stable and is disturbed and disturbed only when the adult gastrointestinal flora is ill or administered, and disorder occurs. When the young and the old are transited to the old, with the increase of clostridium, lactobacillus and enterobacter, bifidobacterium is gradually reduced, and human aging is also gradually shown. With age, the incidence of diseases associated with disturbances of the intestinal flora increases. Under normal physiological conditions, the intestinal flora and the body are in dynamic equilibrium, but when the normal flora is stimulated by physicochemical and biological factors from the inside and outside of the body, the intestinal flora is unbalanced, and diseases are further caused. The causes of the imbalance of the intestinal flora are many, and mainly include dietary changes, diseases, use of antibiotics and the like.
The intestinal mucosa is an important barrier of the organism, and the normal intestinal microecology and the intestinal mucosa barrier interact to jointly maintain the homeostasis of the organism. Once the intestinal microecology is destroyed, the intestinal flora is unbalanced and the barrier of the intestinal mucosa is damaged through various ways, so that harmful pathogenic bacteria invade. The mechanical barrier of the intestinal mucosa is a physical barrier which is formed by tight connection among the intestinal mucosa epithelia, epithelial cells and mucus secreted by the epithelial cells, and bacterial membranes on the surface and can not be freely crossed by endotoxin and bacteria. Once the intestinal epithelial cell tight junction is mutated, reduced or deleted, the permeability of epithelial cell gaps is increased, and bacteria, endotoxin and macromolecular substances can enter the systemic circulation through the gaps. The intestinal mucosa biological barrier is a mutually dependent and restricted microecological balance system formed by the combination of the intestinal flora and the intestinal mucosa. The intestinal bacteria can participate in the formation of biological barriers by secreting various enzymes, prevent or inhibit the invasion of pathogenic bacteria, stimulate the development and maturation of the immune system of a body and regulate the metabolism of the body. The chemical barrier of the intestinal mucosa consists of gastric acid secreted by the digestive tract, lysozyme, mucopolysaccharide, trypsin, bile salt and the like. The intestinal mucosal immune barrier is composed of IgA secreted from the intestinal mucosa and gut-associated lymphoid tissue, etc. Most of IgA in the intestinal tract exists in the form of sIgA, and has the effects of inhibiting intestinal bacteria adhesion, preventing bacterial colonization, inhibiting antigen absorption, neutralizing toxins and the like. The normal flora in the intestinal tract inhibits the excessive proliferation of conditioned pathogens through space occupying effect, nutrition competition, secretion of various metabolites and bacteriocin and the like, and stimulates the development and maturation of the immune system of the organism. Enterotoxin secreted by pathogenic bacteria when the flora is unbalanced increases the permeability of intestinal mucosa, and immunosuppressive protein secreted by the enterotoxin can cause mucosal immune disorder. At present, domestic products for regulating the intestinal flora imbalance mostly focus on increasing the intake of beneficial bacteria, so that the aim of regulating the intestinal flora imbalance is achieved, and the fixed value of the beneficial bacteria in the intestinal tract and the repair of the intestinal mucosa barrier injury are ignored. Therefore, the selection of the types and the amount of beneficial bacteria also needs to control factors causing damage to the intestinal mucosa barrier, so as to better regulate and improve diseases related to the disturbance of the intestinal flora.
In view of this, this patent is filed.
Disclosure of Invention
In order to overcome the defects of the prior art, the invention provides a composition which is prepared from raw materials of isomaltose hypgather, inulin, lactitol, fructo-oligosaccharide, lactobacillus plantarum, stachyose, resistant dextrin, bifidobacterium lactis, bifidobacterium bifidum, lactobacillus acidophilus, bifidobacterium longum, bifidobacterium breve and lactobacillus rhamnosus.
The invention aims to provide a composition for regulating and improving intestinal dysbacteriosis.
Another object of the present invention is to provide a method for preparing a composition for regulating and improving the imbalance of intestinal flora.
The composition for regulating and improving the intestinal dysbacteriosis is prepared from the following raw materials: isomaltose hypgather, inulin, lactitol, fructo-oligosaccharide, lactobacillus plantarum, stachyose, resistant dextrin, bifidobacterium lactis, bifidobacterium bifidum, lactobacillus acidophilus, bifidobacterium longum, bifidobacterium breve and lactobacillus rhamnosus.
According to the specific embodiment of the invention, the composition for regulating and improving the intestinal dysbacteriosis is prepared from the following raw materials in parts by weight: 25-45 parts of isomaltooligosaccharide, 10-30 parts of inulin, 6-14 parts of lactitol, 3.5-15 parts of fructo-oligosaccharide, 3-7 parts of lactobacillus plantarum, 4-12 parts of stachyose, 3-12 parts of resistant dextrin, 0.6-1.4 parts of bifidobacterium lactis, 0.3-0.9 part of bifidobacterium bifidum, 0.8-1.2 parts of lactobacillus acidophilus, 0.4-1.2 parts of bifidobacterium longum, 0.4-0.8 part of bifidobacterium breve and 0.8-1.6 parts of lactobacillus rhamnosus.
According to the specific embodiment of the invention, the composition for regulating and improving the intestinal dysbacteriosis is prepared from the following raw materials in parts by weight: 30-40 parts of isomaltooligosaccharide, 15-25 parts of inulin, 8-12 parts of lactitol, 7.7-14 parts of fructo-oligosaccharide, 4-6 parts of lactobacillus plantarum, 6-10 parts of stachyose, 4-8 parts of resistant dextrin, 0.8-1.2 parts of bifidobacterium lactis, 0.4-0.7 part of bifidobacterium bifidum, 0.9-1.1 part of lactobacillus acidophilus, 0.6-1.0 part of bifidobacterium longum, 0.5-0.7 part of bifidobacterium breve and 1.0-1.4 parts of lactobacillus rhamnosus.
According to the specific embodiment of the invention, the composition for regulating and improving the intestinal dysbacteriosis is prepared from the following raw materials in parts by weight: 35 parts of isomaltooligosaccharide, 20 parts of inulin, 10 parts of lactitol, 11.9 parts of fructo-oligosaccharide, 5 parts of lactobacillus plantarum, 8 parts of stachyose, 5 parts of resistant dextrin, 1 part of bifidobacterium lactis, 0.5 part of bifidobacterium bifidum, 1 part of lactobacillus acidophilus, 0.8 part of bifidobacterium longum, 0.6 part of bifidobacterium breve and 1.2 parts of lactobacillus rhamnosus.
The preparation method of the composition for regulating and improving the intestinal dysbacteriosis comprises the following steps:
(1) preparation of lactobacillus plantarum freeze-dried powder: dissolving frozen lactobacillus plantarum in ice bath, culturing and rejuvenating, fermenting, performing butterfly centrifugation, emulsification embedding, liquid nitrogen deep-cooling granulation, and freeze-drying to obtain lactobacillus plantarum freeze-dried powder;
(2) preparing lactobacillus acidophilus freeze-dried powder: taking out and culturing frozen lactobacillus acidophilus to obtain a fresh production strain, fermenting, performing butterfly centrifugation, emulsification embedding, liquid nitrogen deep-cooling granulation, and freeze-drying to obtain lactobacillus plantarum freeze-dried powder;
(3) preparation of lactobacillus rhamnosus freeze-dried powder: taking out and culturing the frozen lactobacillus rhamnosus to obtain a fresh production strain, fermenting, performing butterfly centrifugation, emulsification embedding, liquid nitrogen deep cooling granulation, and freeze-drying to obtain lactobacillus rhamnosus freeze-dried powder;
(4) mixing: uniformly mixing lactobacillus plantarum freeze-dried powder, stachyose, resistant dextrin, bifidobacterium lactis, bifidobacterium bifidum, lactobacillus acidophilus freeze-dried powder, bifidobacterium longum, bifidobacterium breve and lactobacillus rhamnosus freeze-dried powder, and then adding isomaltooligosaccharide, inulin, lactitol and fructo-oligosaccharide for uniformly mixing to obtain a mixture;
(5) packaging: packaging the mixture to obtain the composition for regulating and improving the intestinal dysbacteriosis.
According to the specific embodiment of the invention, the preparation method of the composition for regulating and improving the intestinal dysbacteriosis comprises the following steps: taking out the frozen lactobacillus plantarum bacterium-protecting tube from a refrigerator, placing the lactobacillus plantarum bacterium-protecting tube in an ice box for ice bath dissolution, then using an inoculating loop to pick seed liquid, streaking the seed liquid on a solid culture medium, and placing the solid culture medium in a constant-temperature incubator at 37 ℃ for culturing for 24-48 hours to rejuvenate strains; selecting a single colony, inoculating the single colony in 5mL of liquid MRS culture medium, and culturing for 18-24h in a constant-temperature incubator at 37 ℃; adding culture medium into the material dissolving tank, stirring for 5-20min, and maintaining the temperature of the material liquid at 55-60 deg.C; sterilizing the feed liquid, and pumping into a fermentation tank, wherein the pasteurization temperature is 105 ℃ and 115 ℃, and the time is 10-30 min; inoculating the seed liquid into the sterilized feed liquid for fermentation at 35-50 ℃ for 30-40 h; stirring in a fermentation tank when the pH value of the fermentation is 4.0-5.0; performing butterfly centrifugation, emulsification embedding, liquid nitrogen deep-cooling granulation and freeze-drying to obtain lactobacillus plantarum freeze-dried powder; the obtained lactobacillus plantarum has good gastrointestinal tract tolerance and the viable bacteria content is 2000 hundred million/gram. The lactobacillus plantarum freeze-dried powder is safe as evaluated by an acute oral toxicity test of mice.
According to the specific embodiment of the invention, the preparation method of the composition for regulating and improving the intestinal dysbacteriosis comprises the following steps of (2): taking out the frozen lactobacillus acidophilus bacteria-protecting tube from a refrigerator, adding the frozen lactobacillus acidophilus bacteria-protecting tube into a fresh skim milk culture medium, placing the fresh skim milk culture medium into a constant-temperature incubator at 37 ℃ for culturing for 8 hours, and obtaining a fresh production strain after curdling; adding the obtained fresh strain culture into a 250mL triangular flask filled with 100mL seed culture medium by 3%, uniformly mixing, and culturing in a constant-temperature incubator at 37 ℃ for 18-24h to obtain a vigorous seed solution; adding culture medium into the material dissolving tank, stirring for 5-20min, and maintaining the temperature of the material liquid at 55-60 deg.C; sterilizing the feed liquid, and pumping into a fermentation tank, wherein the pasteurization temperature is 105 ℃ and 115 ℃, and the time is 10-30 min; inoculating the seed liquid into the sterilized feed liquid for fermentation at the fermentation temperature of 30-50 ℃ for 20-25 h; stirring in a fermentation tank when the pH value of the fermentation is 5.0-6.0; performing butterfly centrifugation, emulsification embedding, liquid nitrogen cryogenic granulation and freeze drying to obtain lactobacillus acidophilus freeze-dried powder; the obtained lactobacillus acidophilus has good gastrointestinal tract tolerance and viable bacteria content of 2000 hundred million/g. The lactobacillus acidophilus freeze-dried powder is safe as evaluated by an acute oral toxicity test of mice.
According to the specific embodiment of the invention, the preparation method of the composition for regulating and improving the intestinal dysbacteriosis comprises the following steps: taking out the frozen lactobacillus rhamnosus bacteria-protecting tube from the refrigerator, adding the frozen lactobacillus rhamnosus bacteria-protecting tube into a fresh skim milk culture medium, placing the fresh skim milk culture medium into a constant-temperature incubator at 37 ℃ for culturing for 8h, and curding to obtain a fresh production strain. Adding the obtained fresh strain culture into a 250mL triangular flask filled with 100mL seed culture medium by 3%, uniformly mixing, and culturing in a constant-temperature incubator at 37 ℃ for 18-24h to obtain a vigorous seed solution; adding culture medium into the material dissolving tank, stirring for 5-20min, and maintaining the temperature of the material liquid at 55-60 deg.C; sterilizing the feed liquid, and pumping into a fermentation tank, wherein the pasteurization temperature is 105 ℃ and 115 ℃, and the time is 10-30 min; inoculating the seed liquid into the sterilized feed liquid for fermentation at 35-45 ℃ for 20-30 h; stirring in a fermentation tank when the pH value of the fermentation is 5.5-6.5; butterfly centrifugation, emulsification embedding, liquid nitrogen deep cooling granulation and freeze drying to obtain lactobacillus rhamnosus freeze-dried powder; the obtained lactobacillus rhamnosus has good gastrointestinal tract tolerance and viable bacteria content of 2000 hundred million/g. The lactobacillus rhamnosus freeze-dried powder is safe as evaluated by an acute oral toxicity test of a mouse.
Among the raw materials, the lactobacillus plantarum has good gastrointestinal tract tolerance, and can still have enough viable count to reach intestinal tract colonization after digestion of gastrointestinal fluid, thereby playing a probiotic role. The compound can be effectively adhered to the intestinal tract of a human body, and the generated short-chain fatty acid can reduce the pH value in the intestinal tract and improve the intestinal environment; meanwhile, bacteriostatic substances such as hydrogen peroxide, bacteriocin and the like can be produced, the growth of common pathogenic bacteria in the intestinal tract, such as pathogenic escherichia coli, salmonella typhimurium, staphylococcus aureus and the like, can be effectively inhibited, and intestinal diseases are prevented; the gamma-aminobutyric acid generated by the metabolism has the effects of tranquilizing nerves and resisting anxiety, and simultaneously can improve the brain activity, promote the metabolism of brain tissues, recover the functions of brain cells and improve the nerve functions.
The bifidobacterium bifidum has good gastrointestinal tract tolerance and can successfully reach the intestinal tract for permanent planting to play a role; can be more effectively adhered to intestinal mucosa to form a biological barrier and protect the intestinal tract; simultaneously, active oxygen free radicals such as DPPH, hydroxyl free radicals, superoxide anions and the like around cells can be eliminated, and the oxidative damage of body cells is reduced; can also promote the high expression of cytokines IL-6, IL-1 beta and IL-12, make the precursor of B cell become the cell producing antibody, enhance the lysis function of natural killer cell, promote the proliferation and secretion of B cell, promote the production of IFN-gamma, and then improve the immunity; IL-12 expressed by the body is stimulated to have the effect of inhibiting IgE synthesis, so that anaphylactic reaction is inhibited; can significantly reduce the total cholesterol and low density lipoprotein in serum of a subject, and has the function of reducing blood fat.
The Bifidobacterium longum is derived from intestinal tract of healthy human body, and has high activity, and has multiple effects of invigorating stomach, regulating intestine, resisting allergy, and enhancing immunity.
The lactobacillus acidophilus can survive in a large amount after digestion in the stomach and intestines; secreted metabolites such as antibiotics and the like can effectively inhibit or kill escherichia coli and staphylococcus aureus, and a layer of biological barrier is formed on intestinal epithelial cells to prevent harmful bacteria from invading; meanwhile, the compound has stronger bile salt hydrolase activity, promotes the catabolism of cholesterol by degrading bile salt, and regulates the redistribution of the cholesterol in blood and liver so as to reduce the cholesterol content in the blood; also has antiallergic effect.
The isomaltooligosaccharide has obvious proliferation effect on beneficial bacteria (bifidobacterium, lactobacillus, bacteroides and the like) and obvious inhibition effect on harmful bacteria (escherichia coli, clostridium, bacteroides and the like).
The proliferation of bifidobacteria and lactobacilli results in the inhibition of the growth of harmful bacteria.
The fructo-oligosaccharide can promote small intestine peristalsis, accelerate degradation and elimination of putrefactive substances in intestinal tract, and has effects of loosening bowel to relieve constipation, improving stool properties, and preventing and relieving constipation. Meanwhile, the fructo-oligosaccharide can quickly proliferate bifidobacteria to form a mycoderm on intestinal mucosa so that germs are difficult to fix, and the bifidobacteria can degrade the fructo-oligosaccharide in a large amount while being cultivated, thereby generating short-chain fatty acid, reducing the pH value of an intestinal cavity, directly inhibiting the growth of the germs and accelerating the propulsion movement of the intestinal cavity.
Inulin has dual functions of dietary fiber and prebiotics. Because of the lack of enzymes for decomposing inulin in human body and animal body, inulin can not be absorbed by stomach and small intestine, but can be fermented by Bacillus bifidus and lactobacillus in colon, thereby promoting intestinal probiotic production, and has Bacillus bifidus proliferation factor effect.
Stachyose can be absorbed by Bacillus bifidus in intestinal tract to promote growth and inhibit proliferation of spoilage bacteria such as Escherichia coli and Clostridium perfringens. Stachyose can be decomposed by beneficial intestinal bacteria such as Bacillus bifidus to generate acetic acid and lactic acid, so as to lower intestinal pH, inhibit growth of harmful bacteria in intestinal tract, and maintain microecological balance in intestinal tract.
Compared with the prior art, the invention has the following beneficial effects:
(1) in the composition for regulating and improving the intestinal dysbacteriosis, the synergistic effect of lactobacillus plantarum, bifidobacterium lactis, bifidobacterium bifidum, lactobacillus acidophilus, bifidobacterium longum, bifidobacterium breve and lactobacillus rhamnosus inhibits the excessive proliferation of pathogenic bacteria through the ways of space occupying effect, nutrition competition, secretion of various metabolites and bacteriocin and the like, and improves the symptoms of halitosis, flatulence and constipation. Secondly, the lactobacillus acidophilus, bifidobacterium bifidum, lactobacillus rhamnosus, isomaltose hypgather and stachyose act together, and the isomaltose hypgather and the stachyose can promote the reproduction of the bifidobacterium, the lactobacillus and the bacteroides; the bifidobacterium is fermented to generate short-chain fatty acid, so that the pH value of the intestinal tract is reduced, mineral elements are released, and the absorption of the mineral is promoted; short chain fatty acids, particularly butyric acid, also stimulate conjunctival cell growth and increase the ion absorption capacity of the intestinal mucosa. The synergistic effect of lactobacillus acidophilus, bifidobacterium bifidum and lactobacillus rhamnosus effectively adheres to intestinal mucosa to form a biological barrier and inhibit bacteria, endotoxin and macromolecular substances from entering systemic circulation through gaps; can eliminate active oxygen free radicals around cells, and reduce oxidative damage of body cells; can make B cell precursor become cell for generating antibody, enhance natural killer cell lysis function, promote B cell proliferation and antibody secretion, promote IFN-gamma generation, further improve immunity, and effectively improve symptoms such as diarrhea, dark complexion, abdominal pain, fatigue, and attention deficit. The lactobacillus acidophilus and the bifidobacterium bifidum have synergistic effect, the lactobacillus acidophilus can obviously reduce the total cholesterol and low-density lipoprotein cholesterol in serum of a subject, the bifidobacterium bifidum has stronger bile salt hydrolase activity, and the bile salt is degraded to promote the catabolism of the cholesterol, so that the cholesterol content in the blood is reduced;
(2) the composition provided by the invention starts from the reasons of the constant value of probiotics in the intestinal tract, the repair of intestinal mucosa barrier damage and the like, and achieves the purpose of effectively regulating and improving the diseases related to the imbalance of the intestinal flora through the mutual matching and synergistic action of the components;
(3) the invention does not add auxiliary materials such as cane sugar, maltodextrin, pigment, essence and the like, and simultaneously adds prebiotics and dietary fibers, promotes the colonization of probiotics in intestinal tracts, is safe and reliable, and can be used as a functional food for improving the intestinal flora imbalance diseases after long-term consumption.
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention more apparent, the technical solutions of the present invention will be described in detail below. It is to be understood that the described embodiments are merely exemplary of the invention, and not restrictive of the full scope of the invention. All other embodiments, which can be derived by a person skilled in the art from the examples given herein without making any creative effort, shall fall within the protection scope of the present invention.
The lactobacillus acidophilus adopted in the invention is LA28 lactobacillus acidophilus, bifidobacterium bifidum is TMC3115 bifidobacterium bifidum, lactobacillus plantarum is LP45 lactobacillus plantarum, bifidobacterium lactis is BAL531 bifidobacterium lactis, lactobacillus rhamnosus is LR519 lactobacillus rhamnosus, bifidobacterium longum is BL693 bifidobacterium longum, and the lactobacillus acidophilus and the bifidobacterium bifidum are all provided by Hebei Yiran biotechnology limited.
Example 1
A composition for regulating and improving intestinal dysbacteriosis is prepared from the following raw materials in parts by weight: 25 parts of isomaltooligosaccharide, 30 parts of inulin, 6 parts of lactitol, 15 parts of fructo-oligosaccharide, 3 parts of lactobacillus plantarum, 4 parts of stachyose, 12 parts of resistant dextrin, 1.4 parts of bifidobacterium lactis, 0.3 part of bifidobacterium bifidum, 1.2 parts of lactobacillus acidophilus, 0.4 part of bifidobacterium longum, 0.8 part of bifidobacterium breve and 0.8 part of lactobacillus rhamnosus.
The preparation method of the composition for regulating and improving the intestinal dysbacteriosis comprises the following steps:
(1) preparation of lactobacillus plantarum freeze-dried powder: taking out the frozen lactobacillus plantarum bacterium-protecting tube from the refrigerator, placing the lactobacillus plantarum bacterium-protecting tube in an ice box for ice bath dissolution, then using an inoculating loop to pick seed liquid, streaking the seed liquid on a solid culture medium, and placing the solid culture medium in a constant-temperature incubator at 37 ℃ for culturing for 24-48h to rejuvenate the strain. And selecting a single colony, inoculating the single colony in 5mL of liquid MRS medium, and culturing for 18-24h in a constant-temperature incubator at 37 ℃. Adding culture medium into the material dissolving tank, stirring for 5-20min, and maintaining the temperature of the material liquid at 55-60 deg.C; sterilizing the feed liquid, and pumping into a fermentation tank, wherein the pasteurization temperature is 105 ℃ and 115 ℃, and the time is 10-30 min; inoculating the seed liquid into the sterilized feed liquid for fermentation at 35-50 ℃ for 30-40 h; stirring in a fermentation tank when the pH value of the fermentation is 4.0-5.0; performing butterfly centrifugation, emulsification embedding, liquid nitrogen deep-cooling granulation and freeze-drying to obtain lactobacillus plantarum freeze-dried powder; the obtained lactobacillus plantarum has good gastrointestinal tract tolerance and the viable bacteria content is 2000 hundred million/gram. The lactobacillus plantarum freeze-dried powder is safe as evaluated by an acute oral toxicity test of a mouse;
(2) preparing lactobacillus acidophilus freeze-dried powder: taking out the frozen lactobacillus acidophilus bacteria-protecting tube from a refrigerator, adding the frozen lactobacillus acidophilus bacteria-protecting tube into a fresh skim milk culture medium, placing the fresh skim milk culture medium into a constant-temperature incubator at 37 ℃ for culturing for 8 hours, and obtaining a fresh production strain after curdling; adding the obtained fresh strain culture into a 250mL triangular flask filled with 100mL seed culture medium by 3%, uniformly mixing, and culturing in a constant temperature incubator at 37 ℃ for 18-24h to obtain a vigorous seed solution; adding culture medium into the material dissolving tank, stirring for 5-20min, and maintaining the temperature of the material liquid at 55-60 deg.C; sterilizing the feed liquid, and pumping into a fermentation tank, wherein the pasteurization temperature is 105 ℃ and 115 ℃, and the time is 10-30 min; inoculating the seed liquid into the sterilized feed liquid for fermentation at the fermentation temperature of 30-50 ℃ for 20-25 h; stirring in a fermentation tank when the pH value of the fermentation is 5.0-6.0; performing butterfly centrifugation, emulsification embedding, liquid nitrogen deep-cooling granulation and freeze-drying to obtain lactobacillus plantarum freeze-dried powder; the obtained lactobacillus acidophilus has good gastrointestinal tract tolerance, and the content of viable bacteria is 2000 hundred million/g; the lactobacillus acidophilus freeze-dried powder is safe as evaluated by an acute oral toxicity test of a mouse;
(3) preparation of lactobacillus rhamnosus freeze-dried powder: taking out the frozen lactobacillus rhamnosus bacteria-protecting tube from the refrigerator, adding the frozen lactobacillus rhamnosus bacteria-protecting tube into a fresh skim milk culture medium, placing the fresh skim milk culture medium into a constant-temperature incubator at 37 ℃ for culturing for 8 hours, and obtaining a fresh production strain after curdling; adding the obtained fresh strain culture into a 250mL triangular flask filled with 100mL seed culture medium by 3%, mixing uniformly, and culturing in a constant temperature incubator at 37 ℃ for 18-24h to obtain a seed solution with vigorous activity. Adding culture medium into the material dissolving tank, stirring for 5-20min, and maintaining the temperature of the material liquid at 55-60 deg.C; sterilizing the feed liquid, and pumping into a fermentation tank, wherein the pasteurization temperature is 105 ℃ and 115 ℃, and the time is 10-30 min; inoculating the seed liquid into the sterilized feed liquid for fermentation at 35-45 ℃ for 20-30 h; stirring in a fermentation tank when the pH value of the fermentation is 5.5-6.5; performing butterfly centrifugation, emulsification embedding, liquid nitrogen deep-cooling granulation and freeze-drying to obtain lactobacillus plantarum freeze-dried powder; the obtained lactobacillus rhamnosus has good gastrointestinal tract tolerance, and the viable bacteria content is 2000 hundred million/g; the lactobacillus rhamnosus freeze-dried powder is safe as evaluated by an acute oral toxicity test of a mouse;
(4) mixing: uniformly mixing lactobacillus plantarum, stachyose, resistant dextrin, bifidobacterium lactis, bifidobacterium bifidum, lactobacillus acidophilus, bifidobacterium longum, bifidobacterium breve and lactobacillus rhamnosus, adding isomaltooligosaccharide, inulin, lactitol and fructo-oligosaccharide, and uniformly mixing to obtain a mixture;
(5) packaging: packaging the mixture to obtain the composition for regulating and improving the diseases related to the disturbance of the intestinal flora.
Example 2
A composition for regulating and improving intestinal dysbacteriosis is prepared from the following raw materials in parts by weight: 30 parts of isomaltooligosaccharide, 25 parts of inulin, 8 parts of lactitol, 14 parts of fructo-oligosaccharide, 4 parts of lactobacillus plantarum, 6 parts of stachyose, 8 parts of resistant dextrin, 1.2 parts of bifidobacterium lactis, 0.4 part of bifidobacterium bifidum, 1.1 part of lactobacillus acidophilus, 0.6 part of bifidobacterium longum, 0.7 part of bifidobacterium breve and 1 part of lactobacillus rhamnosus.
The rest is the same as example 1.
Example 3
A composition for regulating and improving intestinal dysbacteriosis is prepared from the following raw materials in parts by weight: 35 parts of isomaltooligosaccharide, 20 parts of inulin, 10 parts of lactitol, 11.9 parts of fructo-oligosaccharide, 5 parts of lactobacillus plantarum, 8 parts of stachyose, 5 parts of resistant dextrin, 1 part of bifidobacterium lactis, 0.5 part of bifidobacterium bifidum, 1 part of lactobacillus acidophilus, 0.8 part of bifidobacterium longum, 0.6 part of bifidobacterium breve and 1.2 parts of lactobacillus rhamnosus.
The rest is the same as example 1.
Example 4
A composition for regulating and improving intestinal dysbacteriosis is prepared from the following raw materials in parts by weight: 40 parts of isomaltooligosaccharide, 15 parts of inulin, 12 parts of lactitol, 7.7 parts of fructo-oligosaccharide, 6 parts of lactobacillus plantarum, 10 parts of stachyose, 4 parts of resistant dextrin, 0.8 part of bifidobacterium lactis, 0.7 part of bifidobacterium bifidum, 0.9 part of lactobacillus acidophilus, 1 part of bifidobacterium longum, 0.5 part of bifidobacterium breve and 1.4 parts of lactobacillus rhamnosus.
The rest is the same as example 1.
Example 5
A composition for regulating and improving intestinal dysbacteriosis is prepared from the following raw materials in parts by weight: 45 parts of isomaltooligosaccharide, 10 parts of inulin, 14 parts of lactitol, 3.5 parts of fructo-oligosaccharide, 7 parts of lactobacillus plantarum, 12 parts of stachyose, 3 parts of resistant dextrin, 0.6 part of bifidobacterium lactis, 0.9 part of bifidobacterium bifidum, 0.8 part of lactobacillus acidophilus, 1.2 parts of bifidobacterium longum, 0.4 part of bifidobacterium breve and 1.6 parts of lactobacillus rhamnosus.
The rest is the same as example 1.
Comparative example 1
A composition for regulating and improving intestinal dysbacteriosis is prepared from the following raw materials in parts by weight: 20 parts of inulin, 45 parts of lactitol, 11.9 parts of fructo-oligosaccharide, 5 parts of lactobacillus plantarum, 8 parts of stachyose, 5 parts of resistant dextrin, 1 part of bifidobacterium lactis, 0.5 part of bifidobacterium bifidum, 1 part of lactobacillus acidophilus, 0.8 part of bifidobacterium longum, 0.6 part of bifidobacterium breve and 1.2 parts of lactobacillus rhamnosus. The rest is the same as example 1.
Comparative example 2
A composition for regulating and improving intestinal dysbacteriosis is prepared from the following raw materials in parts by weight: 35 parts of isomaltooligosaccharide, 20 parts of inulin, 18 parts of lactitol, 11.9 parts of fructo-oligosaccharide, 5 parts of lactobacillus plantarum, 5 parts of resistant dextrin, 1 part of bifidobacterium lactis, 0.5 part of bifidobacterium bifidum, 1 part of lactobacillus acidophilus, 0.8 part of bifidobacterium longum, 0.6 part of bifidobacterium breve and 1.2 parts of lactobacillus rhamnosus. The rest is the same as example 1.
Comparative example 3
A composition for regulating and improving intestinal dysbacteriosis is prepared from the following raw materials in parts by weight: 35 parts of isomaltooligosaccharide, 20 parts of inulin, 11.5 parts of lactitol, 11.9 parts of fructo-oligosaccharide, 5 parts of lactobacillus plantarum, 8 parts of stachyose, 5 parts of resistant dextrin, 1 part of bifidobacterium lactis, 0.8 part of bifidobacterium longum, 0.6 part of bifidobacterium breve and 1.2 parts of lactobacillus rhamnosus. The rest is the same as example 1.
At least one of general symptoms (diarrhea, abdominal pain, abdominal distension, constipation, acid regurgitation and halitosis) and other symptoms (obesity, allergy, dark complexion, fatigue and attention deficit) of intestinal flora disorder disease is collected, 160 people are aged 30-75 years, 80 men and 80 women are randomly divided into 4 groups, which are respectively a test group, a control group 1, a control group 2 and a control group 3, the test group comprises 40 people, the control group 1 comprises 40 people, the control group 2 comprises 40 people, and the control group 3 comprises 40 people. Volunteers of the test group consumed the composition obtained in example 3 2 times a day, 1 bag each time; volunteers in control group 1 consumed the composition obtained in comparative example 12 times a day, 1 bag each time; volunteers in control group 2 consumed the composition obtained in comparative example 2 times a day, 1 bag each time; volunteers in control group 2 consumed the composition obtained in comparative example 2 times a day, 1 bag each time; after the food is continuously eaten for 3 months, the examination and record are carried out on each group of volunteers, and the results are counted and shown in table 1.
The improvement is as follows: the traditional Chinese medicine composition has more than 2 main clinical symptoms of 11 types of symptoms of diarrhea, abdominal pain, abdominal distension, constipation, acid regurgitation, halitosis, obesity, allergy, dark complexion, fatigue and inattention, and has no other adverse reactions.
Improvement: diarrhea, abdominal pain, abdominal distension, constipation, acid regurgitation, halitosis, obesity, allergy, dark complexion, fatigue, and inattention are improved by 1 of 11 main clinical symptoms, and no other adverse reactions.
And (4) invalidation: diarrhea, abdominal pain, abdominal distension, constipation, acid regurgitation, halitosis, obesity, allergy, dark complexion, fatigue, and inattention do not improve 11 main clinical symptoms, or have adverse reactions.
The effective rate is the percentage of the sum of the improved and improved people and the total people of each group.
TABLE 1 test results
| Group of | Improvement (human) | Improvement (human) | Invalid (human) | Effective rate (%) |
| Test group | 18 | 20 | 2 | 95％ |
| Control group 1 | 16 | 19 | 5 | 87.5％ |
| Control group 2 | 15 | 18 | 7 | 82.5％ |
| Control group 3 | 13 | 17 | 10 | 75％ |
The results in table 1 show that the composition for regulating and improving the disorder of the intestinal flora provided by the invention has a significant improvement effect on the stability of the intestinal flora and the repair of the damage of the intestinal mucosal barrier, and further inhibits the damage of pathogenic bacteria and other factors to the intestinal mucosal barrier. The control group only contains partial components, so the effect of the control group is far inferior to that of the test group, compared with the control group 1, the effective rate of the test group is improved by 7.5%, compared with the control group 2, the effective rate of the test group is improved by 12.5%, compared with the control group 3, the effective rate of the test group is improved by 20%. Wherein the diarrhea, abdominal distension, constipation and halitosis are improved remarkably, and the effective number is 76.9%. The compositions provided by the invention can synergistically improve the effect of regulating and improving the intestinal dysbacteriosis through interaction.
Typical cases
After 1 bag of the composition for regulating and improving the intestinal dysbacteriosis is taken for 20 days continuously, the constipation is relieved, and the defecation is improved from 1 defecation in the previous 5 days to 1 defecation in 2 days, and is smooth. The abdominal distension is relieved, the belly is comfortable and not comfortable, the appetite is good, and a bowl of rice can be eaten at present after a small half bowl is eaten at one time.
For a woman in age of 68, the patient takes the composition for adjusting and improving the intestinal dysbacteriosis, which is obtained in the invention in 1 bag in the morning and evening, and the diarrhea frequency is reduced and the abdominal pain is relieved after the composition is continuously taken for 7 days. After the medicine is continuously taken for 28 days, the abdominal pain feeling disappears, people are more spiritual, and the sleep quality is improved.
If a person who is a male or 60 years old takes the composition for regulating and improving the intestinal dysbacteriosis, which is obtained by the invention and compared with the composition 3, the person takes the composition for regulating and improving the intestinal dysbacteriosis, 1 bag of the composition is respectively taken in the morning and evening, the constipation is relieved after the person takes the composition for 15 days continuously, the defecation is improved from 1 defecation in the previous 5-7 days to 1 in the previous 1 day, and meanwhile, the defecation is smoother. After the oral liquid is taken for 7 days, the abdominal distension disappears and the halitosis is improved.
The composition for regulating and improving the intestinal dysbacteriosis, which is obtained by taking the composition for regulating and improving the intestinal dysbacteriosis of the invention compared with 1 bag of the invention in the morning and at night, is not belch, has smooth defecation and dry stool after being continuously taken for 28 days.
If a woman in 45 years old is obese, dark in face and inattentive, and has insomnia, the composition for adjusting and improving the intestinal dysbacteriosis disease obtained by the comparison 2 of the invention is taken, 1 bag is taken in the morning and evening each day, after the composition is continuously taken for 31 days, the sleeping time is also increased from the original 4-5h to 6-7h, the sleeping time is also spirited in the daytime, the sleeping time is continued to be taken for 40 days, the face is ruddy, the whole person looks spiritual, and the weight is also reduced.
Wangzhi, male, age 54, dark face, diarrhea, emotional instability, taking the composition for regulating and improving the intestinal dysbacteriosis disease obtained by the invention compared with 1, respectively taking 1 bag in the morning and evening each day, and after continuously taking for 10 days, the diarrhea is improved, the diarrhea frequency is reduced, and the abdominal pain is relieved. After the medicine is continuously taken for 63 days, the face is ruddy, the sleeping time is prolonged, and the allergy frequency is reduced.
The above description is only for the specific embodiments of the present invention, but the scope of the present invention is not limited thereto, and any person skilled in the art can easily conceive of the changes or substitutions within the technical scope of the present invention, and all the changes or substitutions should be covered within the scope of the present invention. Therefore, the protection scope of the present invention shall be subject to the protection scope of the appended claims.
Claims (8)
1. A composition for regulating and improving intestinal dysbacteriosis is characterized by being prepared from the following raw materials: isomaltose hypgather, inulin, lactitol, fructo-oligosaccharide, lactobacillus plantarum, stachyose, resistant dextrin, bifidobacterium lactis, bifidobacterium bifidum, lactobacillus acidophilus, bifidobacterium longum, bifidobacterium breve and lactobacillus rhamnosus.
2. The composition for regulating and improving the intestinal dysbacteriosis according to claim 1, which is prepared from the following raw materials in parts by weight: 25-45 parts of isomaltooligosaccharide, 10-30 parts of inulin, 6-14 parts of lactitol, 3.5-15 parts of fructo-oligosaccharide, 3-7 parts of lactobacillus plantarum, 4-12 parts of stachyose, 3-12 parts of resistant dextrin, 0.6-1.4 parts of bifidobacterium lactis, 0.3-0.9 part of bifidobacterium bifidum, 0.8-1.2 parts of lactobacillus acidophilus, 0.4-1.2 parts of bifidobacterium longum, 0.4-0.8 part of bifidobacterium breve and 0.8-1.6 parts of lactobacillus rhamnosus.
3. The composition for regulating and improving the intestinal dysbacteriosis according to claim 1 or 2, which is prepared from the following raw materials in parts by weight: 30-40 parts of isomaltooligosaccharide, 15-25 parts of inulin, 8-12 parts of lactitol, 7.7-14 parts of fructo-oligosaccharide, 4-6 parts of lactobacillus plantarum, 6-10 parts of stachyose, 4-8 parts of resistant dextrin, 0.8-1.2 parts of bifidobacterium lactis, 0.4-0.7 part of bifidobacterium bifidum, 0.9-1.1 part of lactobacillus acidophilus, 0.6-1.0 part of bifidobacterium longum, 0.5-0.7 part of bifidobacterium breve and 1.0-1.4 parts of lactobacillus rhamnosus.
4. The composition for regulating and improving the intestinal dysbacteriosis according to any one of claims 1 to 3, which is prepared from the following raw materials in parts by weight: 35 parts of isomaltooligosaccharide, 20 parts of inulin, 10 parts of lactitol, 11.9 parts of fructo-oligosaccharide, 5 parts of lactobacillus plantarum, 8 parts of stachyose, 5 parts of resistant dextrin, 1 part of bifidobacterium lactis, 0.5 part of bifidobacterium bifidum, 1 part of lactobacillus acidophilus, 0.8 part of bifidobacterium longum, 0.6 part of bifidobacterium breve and 1.2 parts of lactobacillus rhamnosus.
5. The preparation of the composition for regulating and improving the intestinal dysbacteriosis according to claim 1, wherein the preparation method of the composition for regulating and improving the intestinal dysbacteriosis comprises the following steps:
(1) preparation of lactobacillus plantarum freeze-dried powder: dissolving frozen lactobacillus plantarum in ice bath, culturing and rejuvenating, fermenting, performing butterfly centrifugation, emulsification embedding, liquid nitrogen deep-cooling granulation, and freeze-drying to obtain lactobacillus plantarum freeze-dried powder;
(2) preparing lactobacillus acidophilus freeze-dried powder: taking out and culturing frozen lactobacillus acidophilus to obtain a fresh production strain, fermenting, performing butterfly centrifugation, emulsification embedding, liquid nitrogen deep-cooling granulation, and freeze-drying to obtain lactobacillus plantarum freeze-dried powder;
(3) preparation of lactobacillus rhamnosus freeze-dried powder: taking out and culturing the frozen lactobacillus rhamnosus to obtain a fresh production strain, fermenting, performing butterfly centrifugation, emulsification embedding, liquid nitrogen deep cooling granulation, and freeze-drying to obtain lactobacillus rhamnosus freeze-dried powder;
(4) mixing: uniformly mixing lactobacillus plantarum freeze-dried powder, stachyose, resistant dextrin, bifidobacterium lactis, bifidobacterium bifidum, lactobacillus acidophilus freeze-dried powder, bifidobacterium longum, bifidobacterium breve and lactobacillus rhamnosus freeze-dried powder, and then adding isomaltooligosaccharide, inulin, lactitol and fructo-oligosaccharide for uniformly mixing to obtain a mixture;
(5) packaging: packaging the mixture to obtain the composition for regulating and improving the intestinal dysbacteriosis.
6. The method for preparing a composition for regulating and improving the imbalance of intestinal flora according to claim 4, wherein the lactobacillus plantarum lyophilized powder in the step (1) is prepared by the following method: taking out the frozen lactobacillus plantarum bacterium-protecting tube from a refrigerator, placing the lactobacillus plantarum bacterium-protecting tube in an ice box for ice bath dissolution, then using an inoculating loop to pick seed liquid, streaking the seed liquid on a solid culture medium, and placing the solid culture medium in a constant-temperature incubator at 37 ℃ for culturing for 24-48 hours to rejuvenate strains; selecting a single colony, inoculating the single colony in 5mL of liquid MRS culture medium, and culturing for 18-24h in a constant-temperature incubator at 37 ℃; adding culture medium into the material dissolving tank, stirring for 5-20min, and maintaining the temperature of the material liquid at 55-60 deg.C; sterilizing the feed liquid, and pumping into a fermentation tank, wherein the pasteurization temperature is 105 ℃ and 115 ℃, and the time is 10-30 min; inoculating the seed liquid into the sterilized feed liquid for fermentation at 35-50 ℃ for 30-40 h; stirring in a fermentation tank when the pH value of the fermentation is 4.0-5.0; butterfly centrifugation, emulsification embedding, liquid nitrogen deep cooling granulation and freeze-drying to obtain the lactobacillus plantarum freeze-dried powder.
7. The method for preparing a composition for regulating and improving the imbalance of intestinal flora according to claim 4, wherein the Lactobacillus acidophilus lyophilized powder in step (2) is prepared by the following steps: taking out the frozen lactobacillus acidophilus bacteria-protecting tube from a refrigerator, adding the frozen lactobacillus acidophilus bacteria-protecting tube into a fresh skim milk culture medium, placing the fresh skim milk culture medium into a constant-temperature incubator at 37 ℃ for culturing for 8 hours, and obtaining a fresh production strain after curdling; adding the obtained fresh strain culture into a 250mL triangular flask filled with 100mL seed culture medium by 3%, uniformly mixing, and culturing in a constant-temperature incubator at 37 ℃ for 18-24h to obtain a seed solution; adding culture medium into the material dissolving tank, stirring for 5-20min, and maintaining the temperature of the material liquid at 55-60 deg.C; sterilizing the feed liquid, and pumping into a fermentation tank, wherein the pasteurization temperature is 105 ℃ and 115 ℃, and the time is 10-30 min; inoculating the seed liquid into the sterilized feed liquid for fermentation at the fermentation temperature of 30-50 ℃ for 20-25 h; stirring in the fermentation tank when the pH value of the fermentation is 5.0-6.0; butterfly centrifugation, emulsification embedding, liquid nitrogen deep cooling granulation and freeze-drying to obtain the lactobacillus acidophilus freeze-dried powder.
8. The method for preparing the composition for regulating and improving the intestinal dysbacteriosis according to claim 4, wherein the lactobacillus rhamnosus lyophilized powder prepared in the step (3) is prepared by the following steps: taking out the frozen lactobacillus rhamnosus bacteria-protecting tube from the refrigerator, adding the frozen lactobacillus rhamnosus bacteria-protecting tube into a fresh skim milk culture medium, placing the fresh skim milk culture medium into a constant-temperature incubator at 37 ℃ for culturing for 8h, and curding to obtain a fresh production strain. Adding the obtained fresh strain culture into a 250mL triangular flask filled with 100mL seed culture medium by 3%, uniformly mixing, and culturing in a constant-temperature incubator at 37 ℃ for 18-24h to obtain a seed solution; adding culture medium into the material dissolving tank, stirring for 5-20min, and maintaining the temperature of the material liquid at 55-60 deg.C; sterilizing the feed liquid, and pumping into a fermentation tank, wherein the pasteurization temperature is 105 ℃ and 115 ℃, and the time is 10-30 min; inoculating the seed liquid into the sterilized feed liquid for fermentation at 35-45 ℃ for 20-30 h; stirring in a fermentation tank when the pH value of the fermentation is 5.5-6.5; butterfly centrifugation, emulsification embedding, liquid nitrogen deep cooling granulation and freeze-drying to obtain the lactobacillus rhamnosus freeze-dried powder.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210140923.1A CN114504110A (en) | 2022-02-16 | 2022-02-16 | Composition for regulating and improving intestinal dysbacteriosis and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210140923.1A CN114504110A (en) | 2022-02-16 | 2022-02-16 | Composition for regulating and improving intestinal dysbacteriosis and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114504110A true CN114504110A (en) | 2022-05-17 |
Family
ID=81552533
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210140923.1A Pending CN114504110A (en) | 2022-02-16 | 2022-02-16 | Composition for regulating and improving intestinal dysbacteriosis and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114504110A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114921389A (en) * | 2022-07-20 | 2022-08-19 | 广东益可维生物技术有限公司 | Probiotic composition with female intestinal private part nursing and mammary gland anti-inflammatory effects and application thereof |
| CN115944665A (en) * | 2022-10-17 | 2023-04-11 | 天津市宝恒生物科技有限公司 | Probiotic agent for improving intestinal flora balance and preparation method and application thereof |
| CN116004416A (en) * | 2022-07-13 | 2023-04-25 | 四川大学 | Application of bifidobacterium bifidum from infant intestinal tract |
| CN116004416B (en) * | 2022-07-13 | 2024-05-10 | 四川大学 | Application of bifidobacterium bifidum from infant intestinal tract |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109430666A (en) * | 2018-10-15 | 2019-03-08 | 威海养经堂医药科技有限公司 | A kind of Freeze-dry Powder of Probioctics solid beverage |
| CN113025521A (en) * | 2021-03-16 | 2021-06-25 | 河北一然生物科技有限公司 | Preparation process of lactobacillus bulgaricus powder with high fermentation activity |
| CN113455650A (en) * | 2021-07-06 | 2021-10-01 | 彤博士健康产业河北有限公司 | Instant lactobacillus preparation for regulating gastrointestinal flora, relieving constipation and improving immunity |
-
2022
- 2022-02-16 CN CN202210140923.1A patent/CN114504110A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109430666A (en) * | 2018-10-15 | 2019-03-08 | 威海养经堂医药科技有限公司 | A kind of Freeze-dry Powder of Probioctics solid beverage |
| CN113025521A (en) * | 2021-03-16 | 2021-06-25 | 河北一然生物科技有限公司 | Preparation process of lactobacillus bulgaricus powder with high fermentation activity |
| CN113455650A (en) * | 2021-07-06 | 2021-10-01 | 彤博士健康产业河北有限公司 | Instant lactobacillus preparation for regulating gastrointestinal flora, relieving constipation and improving immunity |
Non-Patent Citations (1)
| Title |
|---|
| 宋茂清: "《益生剂及其功效》", 科学技术文献出版社 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116004416A (en) * | 2022-07-13 | 2023-04-25 | 四川大学 | Application of bifidobacterium bifidum from infant intestinal tract |
| CN116004416B (en) * | 2022-07-13 | 2024-05-10 | 四川大学 | Application of bifidobacterium bifidum from infant intestinal tract |
| CN114921389A (en) * | 2022-07-20 | 2022-08-19 | 广东益可维生物技术有限公司 | Probiotic composition with female intestinal private part nursing and mammary gland anti-inflammatory effects and application thereof |
| CN115944665A (en) * | 2022-10-17 | 2023-04-11 | 天津市宝恒生物科技有限公司 | Probiotic agent for improving intestinal flora balance and preparation method and application thereof |
| CN115944665B (en) * | 2022-10-17 | 2023-05-12 | 天津市宝恒生物科技有限公司 | Probiotic agent for improving intestinal flora balance and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hitchins et al. | Prophylactic and therapeutic aspects of fermented milk | |
| CN109123295B (en) | Probiotic solid beverage and preparation method thereof | |
| Hove et al. | Lactic acid bacteria and the human gastrointestinal tract | |
| CN109430666A (en) | A kind of Freeze-dry Powder of Probioctics solid beverage | |
| US20110165127A1 (en) | Dairy-derived probiotic compositions and uses thereof | |
| US20100166721A1 (en) | Probotic compositions and uses thereof | |
| CN111004733B (en) | Bacillus coagulans composite microecological preparation with constipation relieving function | |
| CN114504110A (en) | Composition for regulating and improving intestinal dysbacteriosis and preparation method thereof | |
| CN111955548B (en) | Pure probiotic flavored fermented milk and preparation method thereof | |
| CN111671079A (en) | Composite probiotic powder composition and preparation method thereof | |
| CN101564133A (en) | Soybean yogurt and preparation method thereof | |
| CN110521939A (en) | A kind of probiotics fermention food and preparation method thereof adjusting intestinal health | |
| CN111557404A (en) | Digestion-aiding probiotic solid beverage and preparation method thereof | |
| CN111254088A (en) | Bacillus coagulans strain and application thereof | |
| CN114921363A (en) | Composite probiotics for inhibiting fat accumulation and application thereof | |
| CN103918792A (en) | Xylitol probiotics goat milk tablets and preparation method thereof | |
| CN115120646A (en) | Probiotic composition for balancing intestinal flora and preparation method and application thereof | |
| CN111635875A (en) | Bifidobacterium longum CZ70 and method for preparing live bacterial blackberry fruit pulp by using same | |
| CN113892571A (en) | Active probiotic drink and preparation method thereof | |
| CN106954673A (en) | A kind of dairy products comprising probiotics and preparation method thereof | |
| CN117004503B (en) | Saliva combined lactobacillus MB1 and application thereof in preparation of food and medicine for assisting sleep and regulating intestines and stomach | |
| CN116555075B (en) | Lactobacillus plantarum JF1 and application thereof in preparation of anti-aging food and drug | |
| CN115011513A (en) | Lactic acid bacteria powder for enhancing immunity, regulating intestines and stomach to control fat, losing weight and expelling toxin | |
| CN114686405A (en) | Bifidobacterium bifidum capable of reducing fat, relieving hyperglycemia and regulating intestinal immunity and application thereof | |
| CN113057331A (en) | Novel composite probiotic food |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220517 |